1. Home
  2. TGTX vs TDS Comparison

TGTX vs TDS Comparison

Compare TGTX & TDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.92

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo Telephone and Data Systems Inc.

TDS

Telephone and Data Systems Inc.

HOLD

Current Price

$39.25

Market Cap

4.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
TDS
Founded
1993
1968
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.5B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
TGTX
TDS
Price
$30.92
$39.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$54.75
$49.67
AVG Volume (30 Days)
1.9M
874.0K
Earning Date
11-03-2025
11-07-2025
Dividend Yield
N/A
0.41%
EPS Growth
N/A
N/A
EPS
2.78
N/A
Revenue
$531,898,000.00
$4,859,865,000.00
Revenue This Year
$82.31
N/A
Revenue Next Year
$49.05
N/A
P/E Ratio
$11.08
$82.10
Revenue Growth
100.88
110.05
52 Week Low
$25.28
$31.07
52 Week High
$46.48
$42.74

Technical Indicators

Market Signals
Indicator
TGTX
TDS
Relative Strength Index (RSI) 42.32 53.98
Support Level $30.54 $38.70
Resistance Level $32.26 $40.22
Average True Range (ATR) 1.09 0.92
MACD -0.01 0.09
Stochastic Oscillator 17.47 71.95

Price Performance

Historical Comparison
TGTX
TDS

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

About TDS Telephone and Data Systems Inc.

Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.

Share on Social Networks: